Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 5, 2012, Pages

  Shain, A Hunter ^a   Giacomini, Craig P ^a   Matsukuma, Karen ^a,b   Karikari, Collins A ^b   Bashyam, Murali D ^c   Hidalgo, Manuel ^b,d   Maitra, Anirban ^b   Pollack, Jonathan R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Cancer gene discovery; Comparative genomic hybridization array; Tumor suppressor

Indexed keywords

DNA; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA BINDING; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; MISSENSE MUTATION; MOUSE; NONHUMAN; NONSENSE MUTATION; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; PANCREATIC NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84857129204     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1114817109     Document Type: Article

References (45)

1. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8):S4-S66.
2. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
3. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605-1617.
4. Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A (2008) Pancreatic carcinogenesis. Pancreatology 8:110-125. (Pubitemid 351670364)
5. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20:1218-1249. (Pubitemid 43727584)
6. Massagué J (2008) TGFbeta in Cancer. Cell 134:215-230.
7. PancreaticCancerStrategicPlanWorkgroup (2002) Strategic plan for addressing the recommendations of the pancreatic cancer progress review group. Available at http:// planning.cancer.gov/library/pancreatic.pdf. Accessed September 7, 2011.
8. Jones S, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806.
9. Bashyam MD, et al. (2005) Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia 7:556-562. (Pubitemid 40967756)
10. Aguirre AJ, et al. (2004) High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci USA 101:9067-9072. (Pubitemid 38781612)
11. Kimmelman AC, et al. (2008) Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA 105:19372-19377.
12. Chen S, et al. (2008) Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther 7:1793-1802.
13. Kwei KA, et al. (2008) Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet 4:e1000081.
14. Fu B, Luo M, Lakkur S, Lucito R, Iacobuzio-Donahue CA (2008) Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. Cancer Biol Ther 7:1593-1601.
15. Wood LD, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113. (Pubitemid 350134889)
16. Bignell GR, et al. (2010) Signatures of mutation and selection in the cancer genome. Nature 463:893-898.
17. Su GH, et al. (1998) Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 58:2339-2342. (Pubitemid 28252690)
18. Wang X, et al. (2004) Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J 383:319-325. (Pubitemid 39446693)
19. Reisman D, Glaros S, Thompson EA (2009) The SWI/SNF complex and cancer. Oncogene 28:1653-1668.
20. Weissman B, Knudsen KE (2009) Hijacking the chromatin remodeling machinery: Impact of SWI/SNF perturbations in cancer. Cancer Res 69:8223-8230.
21. Wong AK, et al. (2000) BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 60:6171-6177.
22. Ouyang H, et al. (2000) Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 157:1623-1631.
23. de la Serna IL, Roy K, Carlson KA, Imbalzano AN (2001) MyoD can induce cell cycle arrest but not muscle differentiation in the presence of dominant negative SWI/SNF chromatin remodeling enzymes. J Biol Chem 276:41486-41491.
24. Lee D, et al. (2002) SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem 277:22330-22337. (Pubitemid 34967200)
25. Hill DA, de la Serna IL, Veal TM, Imbalzano AN (2004) BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting homologous recombination or radiation-induced gene activation of p21 or Mdm2. J Cell Biochem 91:987-998.
26. Cheng SW, et al. (1999) c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet 22:102-105.
27. Boukamp P, et al. (1997) Sustained nontumorigenic phenotype correlates with a largely stable chromosome content during long-term culture of the human keratinocyte line HaCaT. Genes Chromosomes Cancer 19:201-214. (Pubitemid 27330230)
28. Xi Q, He W, Zhang XH, Le HV, Massagué J (2008) Genome-wide impact of the BRG1 SWI/SNF chromatin remodeler on the transforming growth factor beta transcriptional program. J Biol Chem 283:1146-1155.
29. Isakoff MS, et al. (2005) Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA 102:17745-17750. (Pubitemid 41803568)
30. Tie F, Furuyama T, Prasad-Sinha J, Jane E, Harte PJ (2001) The Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. Development 128:275-286. (Pubitemid 32124152)
31. van der Vlag J, Otte AP (1999) Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 23:474-478.
32. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21-29.
33. Wilson BG, et al. (2010) Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18:316-328.
34. Roberts CW, Orkin SH (2004) The SWI/SNF complex-Chromatin and cancer. Nat Rev Cancer 4:133-142.
35. Rosson GB, Bartlett C, Reed W, Weissman BE (2005) BRG1 loss in MiaPaCa2 cells induces an altered cellular morphology and disruption in the organization of the actin cytoskeleton. J Cell Physiol 205:286-294. (Pubitemid 41428912)
36. Birnbaum DJ, et al. (2011) Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 50:456-465.
37. Wiegand KC, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532-1543.
38. Jones S, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228-231.
39. Varela I, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469:539-542.
40. Kennison JA, Tamkun JW (1988) Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila. Proc Natl Acad Sci USA 85:8136-8140.
41. Kennison JA (1995) The Polycomb and trithorax group proteins of Drosophila: Transregulators of homeotic gene function. Annu Rev Genet 29:289-303.
42. Tamkun JW, et al. (1992) brahma: A regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 68:561-572.
43. Rubio-Viqueira B, et al. (2006) An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12:4652-4661. (Pubitemid 44297818)
44. Beroukhim R, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci USA 104:20007-20012.
45. Reich M, et al. (2006) GenePattern 2.0. Nat Genet 38:500-501.